Top

Gepubliceerd in:

12-12-2022

Reliability and validity of the simplified Chinese version of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator

Auteurs: Xiangmin Meng, Meimei Shang, Qian Wang, Rong Yan, Kai Jiang, Junai Xiang, Wenhui Liu, Jian Li, Di Wang, Juan Xu

Gepubliceerd in: Quality of Life Research | Uitgave 6/2023

Abstract

Purpose

This study aimed to translate and culturally adapt the immune checkpoint modulator (ICM) subscale of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM) scale and to validate the FACT-ICM scale in Chinese cancer patients receiving immune checkpoint inhibitors (ICIs) treatment.

Methods

In total, 354 cancer patients treated with ICIs were included in our cross-sectional study including 2 phases. Firstly, the ICM subscale was translated and culturally adapted by standardized procedures. Then the FACT-ICM scale was validated, which included item analysis, content validity, floor and ceiling effects, internal consistency reliability, test–retest reliability, construct validity, convergent/divergent validity, and known-group validity.

Results

The content validity indexes at the item and scale level of the ICM subscale were greater than 0.8. No floor and ceiling effects were found. The Cronbach’s α and McDonald’s omega coefficients of the simplified Chinese version of the FACT-ICM scale were 0.935 and 0.936, and the intraclass correlation coefficient was 0.833 (95% confidence interval: 0.574–0.940). Confirmatory factor analysis confirmed the 5-subscale structure of the simplified Chinese version of the FACT-ICM scale (χ²/df = 2.144, RMSEA = 0.057, SRMR = 0.072, and CFI = 0.848). Convergent and divergent validity further supported the construct validity of the simplified Chinese version of the FACT-ICM scale. The known-group validity of the simplified Chinese version of the FACT-ICM scale was confirmed in patients with different physical statuses.

Conclusions

The simplified Chinese version of the FACT-ICM scale is a valid and reliable instrument and can be used in clinical practice and research on cancer patients receiving ICIs treatment.

vorige artikel Cross-sectional study examining psychometric properties of the Slovenian version of the 14-item Resilience Scale (RS-14-SL)

volgende artikel Development of a standard set of PROs and generic PROMs for Dutch medical specialist care

Guideline Working Committee of Chinese society of clinical oncology. (2021). Guidelines for clinical use of immune checkpoint inhibitors. People's health press.

Shaaban, M., Othman, H., Ibrahim, T., Ali, M., Abdelmoaty, M., Abdel-Kawi, A. R., Mostafa, A., El Nakeeb, A., Emam, H., & Refaat, A. (2020). Immune checkpoint regulators: A new era toward promising cancer therapy. Current Cancer Drug Targets, 20(6), 429–460. https://doi.org/10.2174/1568009620666200422081912CrossRefPubMed

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., Ernstoff, M. S., Frigault, M., Kaffenberger, B. H., Lunning, M., McGettigan, S., McPherson, J., Mohindra, N. A., Naidoo, J., Olszanski, A. J., … Engh, A. (2020). NCCN guidelines insights: Management of immunotherapy-related toxicities, version 1.2020. Journal of the National Comprehensive Cancer Network, 18(3), 230–241. https://doi.org/10.6004/jnccn.2020.0012CrossRefPubMed

Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017). Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of oncology, 28((suppl_4)), iv119–iv142. https://doi.org/10.1093/annonc/mdx225CrossRefPubMed

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine, 378(2), 158–168. https://doi.org/10.1056/NEJMra1703481CrossRefPubMed

Schneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Davies, M. J., Ernstoff, M. S., Fecher, L., Ghosh, M., Jaiyesimi, I., Mammen, J. S., Naing, A., Nastoupil, L. J., Phillips, T., … Bollin, K. (2021). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. Journal of Clinical Oncology, 39(36), 4073–4126. https://doi.org/10.1200/jco.21.01440CrossRefPubMed

Ala-Leppilampi, K., Baker, N. A., McKillop, C., Butler, M. O., Siu, L. L., Spreafico, A., Abdul, A. R., Razak, A. M., Joshua, D. H., Bedard, P. L., Leighl, N., Oza, A. M., Parsons, J. A., & Hansen, A. R. (2020). Cancer patients’ experiences with immune checkpoint modulators: A qualitative study. Cancer Medicine, 9(9), 3015–3022. https://doi.org/10.1002/cam4.2940CrossRefPubMedPubMedCentral

Cappelli, L. C., Grieb, S. M., Shah, A. A., Bingham, C. O., 3rd., & Orbai, A. M. (2020). Immune checkpoint inhibitor-induced inflammatory arthritis: A qualitative study identifying unmet patient needs and care gaps. BMC Rheumatol, 4, 32. https://doi.org/10.1186/s41927-020-00133-8CrossRefPubMedPubMedCentral

Di Maio, M., Gallo, C., Leighl, N. B., Piccirillo, M. C., Daniele, G., Nuzzo, F., Gridelli, C., Gebbia, V., Ciardiello, F., De Placido, S., Ceribelli, A., Favaretto, A. G., de Matteis, A., Feld, R., Butts, C., Bryce, J., Signoriello, S., Morabito, A., Rocco, G., & Perrone, F. (2015). Symptomatic toxicities experienced during anticancer treatment: Agreement between patient and physician reporting in three randomized trials. Journal of Clinical Oncology, 33(8), 910–915. https://doi.org/10.1200/JCO.2014.57.9334CrossRefPubMed

10.

Miura, Y., Ando, M., Yamazaki, K., Hironaka, S., Boku, N., Muro, K., & Hyodo, I. (2021). Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: A post hoc analysis (WJOG4407GSS2). Supportive Care in Cancer, 29(7), 3715–3723. https://doi.org/10.1007/s00520-020-05891-2CrossRefPubMed

11.

Health, U. S. D. o., Human Services, F. D. A. C. f. D. E., Research, Health, U. S. D. o., Human Services, F. D. A. C. f. B. E., Research, Radiological, H. (2006). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance. Health and Quality of Life Outcomes, 4, 79. https://doi.org/10.1186/1477-7525-4-79CrossRef

12.

Basch, E., Deal, A. M., Kris, M. G., Scher, H. I., Hudis, C. A., Sabbatini, P., Rogak, L., Bennett, A. V., Dueck, A. C., Atkinson, T. M., Chou, J. F., Dulko, D., Sit, L., Barz, A., Novotny, P., Fruscione, M., Sloan, J. A., & Schrag, D. (2016). Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. Journal of Clinical Oncology, 34(6), 557–565. https://doi.org/10.1200/JCO.2015.63.0830CrossRefPubMed

13.

Howell, D., Molloy, S., Wilkinson, K., Green, E., Orchard, K., Wang, K., & Liberty, J. (2015). Patient-reported outcomes in routine cancer clinical practice: A scoping review of use, impact on health outcomes, and implementation factors. Annals of Oncology, 26(9), 1846–1858. https://doi.org/10.1093/annonc/mdv181CrossRefPubMed

14.

Hall, E. T., Singhal, S., Dickerson, J., Gabster, B., Wong, H. N., Aslakson, R. A., & Schapira, L. (2019). Patient-reported outcomes for cancer patients receiving checkpoint inhibitors: Opportunities for palliative care-a systematic review. Journal of Pain and Symptom Management, 58(1), 137-156.e131. https://doi.org/10.1016/j.jpainsymman.2019.03.015CrossRefPubMed

15.

Colomer-Lahiguera, S., Bryant-Lukosius, D., Rietkoetter, S., Martelli, L., Ribi, K., Fitzpatrick-Lewis, D., Sherifali, D., Orcurto, A., Juergens, R., & Eicher, M. (2020). Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: A systematic review. J Patient Rep Outcomes, 4(1), 58. https://doi.org/10.1186/s41687-020-00210-zCrossRefPubMedPubMedCentral

16.

Safa, H., Tamil, M., Spiess, P. E., Manley, B., Pow-Sang, J., Gilbert, S. M., Safa, F., Gonzalez, B. D., Oswald, L. B., Semaan, A., Diab, A., & Chahoud, J. (2020). Patient reported outcomes in clinical trials leading to cancer immunotherapy drug approvals from 2011 to 2018: A systematic review. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaa174CrossRefPubMedCentral

17.

Voon, P. J., Cella, D., & Hansen, A. R. (2021). Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies. Cancer, 127(9), 1360–1368. https://doi.org/10.1002/cncr.33457CrossRefPubMed

18.

Da Silva Lopes, A. M., Colomer-Lahiguera, S., Alfonso, N. M., Aedo-Lopez, V., Spurrier-Bernard, G., Tolstrup, L. K., Pappot, H., Aspeslagh, S., Rogiers, A., Neyns, B., Haanen, J. B., Mitchell, S. A., Addeo, A., Michielin, O., & Eicher, M. (2021). Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A delphi study. European Journal of Cancer, 157, 225–237. https://doi.org/10.1016/j.ejca.2021.08.026CrossRefPubMed

19.

Hansen, A. R., Ala-Leppilampi, K., McKillop, C., Siu, L. L., Bedard, P. L., Abdul, A. R., Razak, A. S., Sridhar, S. S., Leighl, N., Butler, M. O., Hogg, D., Sacher, A., Oza, A. M., Al-Agha, R., Maurice, C., Chan, C. T., Shapera, S., Feld, J. J., Nisenbaum, R., … Parsons, J. (2020). Development of the functional assessment of cancer therapy-immune checkpoint modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. Cancer, 126(7), 1550–1558. https://doi.org/10.1002/cncr.32692CrossRefPubMed

20.

Smith, A. B., Wright, P., Selby, P. J., & Velikova, G. (2007). A rasch and factor analysis of the functional assessment of cancer therapy-general (FACT-G). Health and Quality of Life Outcomes, 5, 19. https://doi.org/10.1186/1477-7525-5-19CrossRefPubMedPubMedCentral

21.

Wan, C., Meng, Q., Tang, X., Zhang, C., Luo, J., & Zhang, X. (2006). Evaluation of the simplified Chinese version of the cancer patients quality of life scale (FACT-G). Journal of practical oncology, 21(1), 77–80. https://doi.org/10.3969/j.issn.1001-1692.2006.01.027CrossRef

22.

Eremenco, S. L., Cella, D., & Arnold, B. J. (2005). A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation and the Health Professions, 28(2), 212–232. https://doi.org/10.1177/0163278705275342CrossRefPubMed

23.

Wu, M. (2010). Questionnaire statistical analysis practice-SPSS operation and application. Chongqing University Press.

24.

Cong, W., Wu, Y., Liu, L., Hu, M., & Zhou, C. (2020). A Chinese version of the chemotherapy-induced alopecia distress scale based on reliability and validity assessment in breast cancer patients. Supportive Care in Cancer, 28(9), 4327–4336. https://doi.org/10.1007/s00520-019-05284-0CrossRefPubMed

25.

Bujang, M. A., & Baharum, N. (2017). A simplified guide to determination of sample size requirements for estimating the value of intraclass correlation coefficient: A review. Archives of Orofacial Science, 12(1), 1–11.

26.

FACIT. (2021). FACT-ICM Scoring Downloads. Retrieved July 16, 2022, from https://www.facit.org/measures-scoring-downloads/fact-icm-scoring-downloads

27.

Osoba, D., Zee, B., Pater, J., Warr, D., Kaizer, L., & Latreille, J. (1994). Psychometric properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Quality of Life Research, 3(5), 353–364. https://doi.org/10.1007/BF00451727CrossRefPubMed

28.

Zhao, H., & Kanda, K. (2004). Testing psychometric properties of the standard chinese version of the European organization for research and treatment of cancer quality of life core questionnaire 30 (EORTC QLQ-C30). Journal of Epidemiology, 14(6), 193–203. https://doi.org/10.2188/jea.14.193CrossRefPubMed

29.

FACIT. (2021). Scoring OF THE FACIT MEASURES. Retrieved July 12, 2022, from https://www.facit.org/scoring

30.

Zhao, H., Wu, Y., Tao, Y., Zhou, C., De Vrieze, T., Li, X., & Chen, L. (2022). Psychometric validation of the Chinese version of the lymphedema functioning, disability, and health questionnaire for upper limb lymphedema in patients with breast cancer-related lymphedema. Cancer Nursing, 45(1), 70–82. https://doi.org/10.1097/NCC.0000000000000848CrossRefPubMed

31.

Polit, D. F., Beck, C. T., & Owen, S. V. (2007). Is the CVI an acceptable indicator of content validity? Appraisal and recommendations. Res Nurs Health, 30(4), 459–467. https://doi.org/10.1002/nur.20199CrossRefPubMed

32.

Radulesco, T., Mancini, J., Penicaud, M., Grob, J. J., Richard, M. A., Dessi, P., Malissen, N., & Michel, J. (2021). Cross-cultural adaptation into French and validation of the SCAR-Q questionnaire. Quality of Life Research, 30(4), 1225–1231. https://doi.org/10.1007/s11136-020-02719-8CrossRefPubMed

33.

Bland, J. M., & Altman, D. G. (1997). Cronbach’s alpha. BMJ, 314(7080), 572. https://doi.org/10.1136/bmj.314.7080.572CrossRefPubMedPubMedCentral

34.

Sung, H. C., Su, H. F., Wang, H. M., Koo, M., & Lo, R. Y. (2021). Psychometric properties of the dementia knowledge assessment scale-traditional Chinese among home care workers in Taiwan. BMC Psychiatry, 21(1), 515. https://doi.org/10.1186/s12888-021-03530-6CrossRefPubMedPubMedCentral

35.

Shoukri, M. M., Asyali, M., & Donner, A. (2004). Sample size requirements for the design of reliability study: Review and new results. Statistical Methods in Medical Research, 13(4), 251–271.CrossRef

36.

FACIT. (2021). Functional assessment of cancer therapy – immune checkpoint modulator for patients receiving immunotherapy treatment. Retrieved July 16, 2022, from https://www.facit.org/measures/FACT-ICM

37.

MacCallum, R. C., Browne, M. W., & Sugawara, H. M. (1996). Power analysis and determination of sample size for covariance structure modeling. Psychological methods, 1(2), 130.CrossRef

38.

Marsh, H. W., Hau, K. T., Balla, J. R., & Grayson, D. (1998). Is more ever too much? The number of indicators per factor in confirmatory factor analysis. Multivariate Behav Res, 33(2), 181–220. https://doi.org/10.1207/s15327906mbr3302_1CrossRefPubMed

39.

Streiner, D. L., Norman, G. R., & Cairney, J. (2015). Health measurement scales: A practical guide to their development and use. Oxford University Press.CrossRef

40.

Zhang, X., Mo, Y., Yan, C., Li, Y., & Li, H. (2021). Psychometric properties of two abbreviated connor-davidson resilience scales in Chinese infertile couples. Quality of Life Research, 30(8), 2405–2414. https://doi.org/10.1007/s11136-021-02820-6CrossRefPubMed

41.

Villabø, M. A., Oerbeck, B., Skirbekk, B., Hansen, B. H., & Kristensen, H. (2016). Convergent and divergent validity of K-SADS-PL anxiety and attention deficit hyperactivity disorder diagnoses in a clinical sample of school-aged children. Nordic journal of psychiatry, 70(5), 358–364. https://doi.org/10.3109/08039488.2015.1125944CrossRefPubMed

42.

Degboe, A., Ivanescu, C., Rohay, J. M., Turner, R. R., & Cella, D. (2019). Validity and performance of the functional assessment of cancer therapy-bladder (FACT-Bl) among advanced urothelial cancer patients. Supportive Care in Cancer, 27(11), 4189–4198. https://doi.org/10.1007/s00520-019-04709-0CrossRefPubMedPubMedCentral

43.

Schober, P., Boer, C., & Schwarte, L. A. (2018). Correlation coefficients: Appropriate use and interpretation. Anesthesia & Analgesia, 126(5), 1763–1768. https://doi.org/10.1213/ANE.0000000000002864CrossRef

44.

Zhang, L., Yan-Jun, S., Chen, J. Y., Liao, Z. C., Luo, Z. Q., Xie, S. M., Zhang, J., Lin, Y. S., Guo, H., Sun, W. L., Pekbay, B., Miller, A. R., Luo, L., Rui, Y. H., Li, M. H., & Wang, C. L. (2016). Validation of the Chinese version of EORTC QLQ-BM22 in patients with bone metastases. Supportive Care in Cancer, 24(3), 1019–1024. https://doi.org/10.1007/s00520-015-2870-yCrossRefPubMed

45.

Wong, C. K., Choi, E. P., Tsu, J. H., Ho, B. S., Ng, A. T., Chin, W. Y., & Yiu, M. K. (2015). Psychometric properties of functional assessment of cancer therapy-prostate (FACT-P) in Chinese patients with prostate cancer. Quality of Life Research, 24(10), 2397–2402. https://doi.org/10.1007/s11136-015-0993-8CrossRefPubMed

46.

Levy, D., Dhillon, H. M., Lomax, A., Marthick, M., McNeil, C., Kao, S., & Lacey, J. (2019). Certainty within uncertainty: A qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Supportive Care in Cancer, 27(5), 1845–1852. https://doi.org/10.1007/s00520-018-4443-3CrossRefPubMed

47.

Brant, J. M., Beck, S., & Miaskowski, C. (2010). Building dynamic models and theories to advance the science of symptom management research. Journal of Advanced Nursing, 66(1), 228–240. https://doi.org/10.1111/j.1365-2648.2009.05179.xCrossRefPubMed

48.

Schag, C. A., Ganz, P. A., Wing, D. S., Sim, M. S., & Lee, J. J. (1994). Quality of life in adult survivors of lung, colon and prostate cancer. Quality of Life Research, 3(2), 127–141. https://doi.org/10.1007/BF00435256CrossRefPubMed

Titel: Reliability and validity of the simplified Chinese version of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator
Auteurs: Xiangmin Meng
Meimei Shang
Qian Wang
Rong Yan
Kai Jiang
Junai Xiang
Wenhui Liu
Jian Li
Di Wang
Juan Xu
Publicatiedatum: 12-12-2022
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 6/2023
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-022-03318-5

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusions

Log in om toegang te krijgen

Andere artikelen Uitgave 6/2023

Quality of life in postmenopausal women with osteoporosis: a systematic review and meta-analysis

The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrument

Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism

Health-related quality of life in seven European countries throughout the course of the COVID-19 pandemic: evidence from the European COvid Survey (ECOS)

The associations between HIV stigma and mental health symptoms, life satisfaction, and quality of life among Black sexual minority men with HIV

Establishing severity levels for patient-reported measures of functional communication, participation, and perceived cognitive function for adults with acquired cognitive and language disorders